Journal article

Determining research priorities for clinician-initiated trials in infectious diseases

David L Paterson

Medical Journal of Australia | WILEY | Published : 2013

Grants

Funding Acknowledgements

Tania Sorrell has received untied research funds from Gilead Sciences, Merck, Sharp & Dohme and Pfizer Pharmaceuticals and has been a member of their respective antifungal advisory boards Sharon Chen has served on the antifungal advisory boards of Pfizer Australia, Merck, Sharp & Dohme and Gilead Sciences and has received educational grants from Pfizer Australia, Merck, Sharp & Dohme and Gilead Sciences. Narin Bak has received financial sponsorship for travel-related educational meetings from Merck, Sharp & Dohme, Gilead Sciences and Pfizer and honoraria for educational lectures from Merck, Sharp & Dohme. He has undertaken clinical trials with antivirals and other antibiotics for many other pharmaceutical companies. David Paterson has served as a consultant or on advisory boards for AstraZeneca, Merck, Sharp & Dohme, Pfizer, Cubist, Leo Pharmaceuticals, Novartis, Johnson and Johnson, Bayer, Trius and Achaogen, and has received honoraria for educational lectures from AstraZeneca and research funds from Sanofi Aventis.